NEW Our free Dividend Tracker is live — see what your stocks pay you

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

MAZE | NASDAQ

$27.18 $0.16 | 0.59%

SIGNAL:

|2026-09-29 |F&G 38 |RSI 54.3

Add to favoritesFavorite

Company Overview:

Market Cap: $1.51B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $21.95 - $53.65

1.7 Year MAZE Performance Metrics:

Total Return (with DRIP): 70.4% (36.83% CAGR)

Total Return (no DRIP): 70.4% (36.83% CAGR)

Share Price: 70.4% (36.83% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $17,041

Total Return $ (with DRIP): $7,041

MAZE Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

MAZE Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

MAZE Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

MAZE - Revenue

MAZE Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Earnings Per Share (EPS)

MAZE EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Net Income

🔓 See the full chart40% off right now · 7-day free trial

MAZE Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

MAZE EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

MAZE Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

MAZE Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

MAZE Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

MAZE Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

MAZE Shares Outstanding CAGR:1Y: 34.54%2Y: 16.07%5Y: 0.00%10Y: 0.00%

MAZE - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

MAZE Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

MAZE Stock-Based Comp CAGR:1Y: 183.81%2Y: 107.10%5Y: 0.00%10Y: 0.00%

MAZE - Expenses

🔓 See the full chart40% off right now · 7-day free trial

MAZE Expenses CAGR:1Y: -72.77%2Y: -18.22%5Y: 0.00%10Y: 0.00%

MAZE - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

MAZE - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

MAZE - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

MAZE - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

MAZE - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

MAZE - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

MAZE - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

MAZE Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

MAZE - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

MAZE Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

MAZE Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

MAZE Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

MAZE Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

MAZE - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

MAZE Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

MAZE Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

MAZE Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

MAZE Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

MAZE Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

MAZE - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

MAZE Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for MAZE

Based on past 1.7-year performance, here are MAZE growth metrics:

Share price CAGR of +36.83%
Dividend CAGR of +0%

Using MAZE CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	MAZE (DRIP)	MAZE - No DRIP
Current Price	$27.18	$27.18
Start Shares	367.92	367.92
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	367.92	367.92
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$27.18	$27.18
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - MAZE

NOTE: Above numbers are our estimate based on MAZE's Dividend and Price CAGR over past 1.7 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Maze Therapeutics, Inc. (MAZE) had its IPO on 2025-01-31, and is traded on NASDAQ stock exchange.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

MAZE website: https://www.mazetx.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

DCF Model — MAZE

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $27.18

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →